替诺福韦酯富马酸富马酸在整个怀孕期间对患有慢性乙型肝

StephenW

Eur J Gastroenterol Hepatol. 2019 Dec 31. doi: 10.1097/MEG.0000000000001662. [Epub ahead of print]
The safety and efficacy of tenofovir disoproxil fumarate used throughout pregnancy for mothers with chronic hepatitis B.
Gao X1, Duan X1, Cai H2, Hu Y3, Liu M3, Kang K3, Zhou M3, Fu D3, Yi W3.
Author information

1
    Department of General Medicine.
2
    Hepatology Clinic.
3
    Department of Obstetrics and Gynecology, Beijing Ditan Hospital, Capital Medical University, Beijing, China.

Abstract
BACKGROUND:

Antiviral therapy throughout pregnancy in women with chronic hepatitis B (CHB) during pregnancy has been suggested; however, the data of tenofovir disoproxil fumarate (TDF) are limited. The aim of this study was to evaluate the safety and efficiency in women with CHB.
METHODS:

It was a single-center, retrospectively study. Eighty-one women received TDF 300 mg/day before pregnancy. Sixty-three women did not receive antiviral treatment. All infants in both groups received immunoprophylaxis. Mothers and infants were followed at least postpartum 7 months. The primary endpoint was the safety of mothers and infants. The secondary endpoints were mother-to-child transmission (MTCT) rate and hepatitis B virus (HBV) DNA suppression.
RESULTS:

TDF was well tolerated in the mothers. The rates of neonatal congenital abnormalities were similar between the two groups (3.7% or 3/81 versus 3.3% or 2/63, P = 1.000). There were also no significant differences in infant length and weight, Apgar score (1 minute), rate of low birth weight, gestational age, or rate of cesarean section between the two groups. TDF significantly reduced the viral load (3.4 ± 0.5 log IU/mL versus 6.3 ± 1.5 log IU/mL, P < 0.001) and the ALT levels (19.9 ± 10.2 versus 46.8 ± 44.8 U/L, P < 0.001) before delivery. At 7-month postpartum, the MTCT rate was 0% in the TDF-treated group when compared with 6.3% (4/63) in the untreated group (P = 0.035).
CONCLUSION:

TDF used throughout pregnancy can safely reduce the rate of MTCT.

PMID:
    31895914
DOI:
    10.1097/MEG.0000000000001662

StephenW

Eur J胃肠肝素。 2019年12月31日。doi：10.1097 / MEG.0000000000001662。 [Epub提前发布]
替诺福韦酯富马酸富马酸在整个怀孕期间对患有慢性乙型肝炎的母亲的安全性和有效性。
高X1，段X1，蔡H2，胡Y3，刘M3，康K3，周M3，付D3，易W3。
作者信息

1个
    普通科。
2
    肝病诊所。
3
    首都医科大学附属北京地坛医院妇产科，北京

抽象
背景：

有人建议在怀孕期间患有慢性乙型肝炎（CHB）的妇女在整个怀孕期间进行抗病毒治疗；然而，替诺福韦富马酸替诺福韦酯（TDF）的数据有限。这项研究的目的是评估患有CHB的女性的安全性和有效性。
方法：

这是一项单中心回顾性研究。八十一名妇女在怀孕前每天接受300毫克的TDF。 63名妇女未接受抗病毒治疗。两组中的所有婴儿均接受了免疫预防。母亲和婴儿至少在产后7个月被随访。主要终点是母亲和婴儿的安全。次要终点是母婴传播率（MTCT）和乙肝病毒（HBV）DNA抑制。
结果：

母亲对TDF的耐受性良好。两组的新生儿先天性异常发生率相似（3.7％或3/81比3.3％或2/63，P = 1.000）。两组的婴儿身长和体重，Apgar评分（1分钟），低出生体重率，胎龄或剖宫产率也无显着差异。 TDF显着降低了分娩前的病毒载量（3.4±±0.5 log IU / mL与6.3±±1.5 log IU / mL，P <0.001）和ALT水平（19.9±±10.2对46.8±44.8 U / L，P <0.001）。产后7个月，TDF治疗组的MTCT率为0％，而未治疗组的6.3％（4/63）（P = 0.035）。
结论：

整个怀孕期间使用的TDF可以安全地降低MTCT发生率。

PMID：
    31895914
DOI：
    10.1097 / MEG.0000000000001662